Quelle: Journal of the National Cancer Institute

Die regelmäßige Einnahmen von Aspirin ist offenbar in der Lage, die Häufigkeit des Vorkommens von Bauchspeicheldrüsen-Krebs (Pankreas Karzinom) deutlich zu vermindern.

Journal of the National Cancer Institute, Vol. 94, No. 15, 1168-1171, August 7, 2002
© 2002 Oxford University Press
 

Association Between Nonsteroidal Anti-Inflammatory Drug Use and the Incidence of Pancreatic Cancer

Kristin E. Anderson, Trista W. Johnson, DeAnn Lazovich, Aaron R. Folsom

Affiliation of authors: Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis.

Correspondence to: Kristin E. Anderson, Ph.D., Division of Epidemiology, University of Minnesota, 1300 S. Second St., #300, Minneapolis, MN 55454 (e-mail: anderson_k@epi.umn.edu).

ABSTRACT

Laboratory studies indicate that nonsteroidal anti-inflammatory drugs (NSAIDs) may inhibit pancreatic cancer, but epidemiologic data to support this finding are limited. We conducted a prospective study from 1992 through 1999 among 28 283 postmenopausal women who lived in Iowa to examine the association between the self-reported use of aspirin and other NSAIDs and the incidence of pancreatic cancer. Eighty incident cases of pancreatic cancer were identified during 7 years of follow-up.

The multivariate-adjusted relative risk of pancreatic cancer associated with any current use of aspirin versus no use was 0.57 (95% confidence interval = 0.36 to 0.90). There was a trend of decreasing risk of pancreatic cancer incidence with increasing frequency of aspirin use per week (P_trend = .005). Nonaspirin NSAID use was not associated with incident pancreatic cancer. These data indicate that aspirin might be chemopreventive for pancreatic cancer.

This article has been cited by other articles:

• Gottlieb, S. (2002). Aspirin shown to reduce risk of pancreatic cancer. BMJ 325: 356-356 [Full Text]  

mehr Informationen (Originalquelle)